Thermo Fisher Scientific Inc. $TMO Shares Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 54,492 shares of the medical research company’s stock after acquiring an additional 3,252 shares during the period. New York Life Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $31,575,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. grew its holdings in Thermo Fisher Scientific by 13,800.0% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 417 shares of the medical research company’s stock valued at $243,000 after purchasing an additional 414 shares during the period. Plancorp LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.8% in the 4th quarter. Plancorp LLC now owns 1,120 shares of the medical research company’s stock valued at $649,000 after purchasing an additional 51 shares during the last quarter. Western Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 32.6% during the 4th quarter. Western Wealth Management LLC now owns 4,494 shares of the medical research company’s stock valued at $2,604,000 after buying an additional 1,104 shares during the period. Castle Rock Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 2.1% during the 4th quarter. Castle Rock Wealth Management LLC now owns 3,667 shares of the medical research company’s stock worth $2,091,000 after buying an additional 76 shares during the last quarter. Finally, Proactive Wealth Strategies LLC raised its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Proactive Wealth Strategies LLC now owns 745 shares of the medical research company’s stock worth $432,000 after buying an additional 30 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. Citigroup boosted their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. DZ Bank assumed coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective on the stock. Barclays dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, Royal Bank Of Canada set a $490.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $616.10.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.5%

NYSE TMO opened at $448.12 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The business has a 50 day moving average price of $487.50 and a two-hundred day moving average price of $542.85. The stock has a market cap of $166.53 billion, a PE ratio of 24.64, a P/E/G ratio of 1.97 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.